IDAC Theranostics, Inc.

                                                                                                                                         17th May 2016

                   IDAC Enters an agreement with ONO PHARMACEUTICAL relating to
            Exclusive Evaluation and License Negotiation on IT1208, anti-CD4 antibody


IDAC Theranostics, Inc. (Tokyo, Japan; President, Satoru Ito; gIDACh) announced that it entered into

an option agreement with ONO PHARMACEUTICAL CO., LTD. (Osaka, Japan; President, Representative

Director, Gyo Sagara; hONOh) on May 16, 2016, under with ONO is granted a right for exclusive evaluation

and license negotiation on IT1208, a humanized anti-CD4 antibody being developed by IDAC.

During the term of such agreement, IDAC will conduct Phase‡Tstudy of IT1208 in solid tumors in Japan.

IT1208 transiently depletes CD4+ T cells and removes an immunosuppressive environment, leading to

activation of antitumor immunity mediated mainly by CD8+ T cells. In preclinical studies, anti-CD4 antibody

has demonstrated a potent antitumor activity in tumor-bearing mice.

About anti CD4 antibody(IT1208)
IT1208 is a humanized anti-CD4 antibody with an enhanced antibody-dependent-cellular cytotoxicity(ADCC)

activity using Potelligent technology from Kyowa Hakko Kirin Co., Ltd.

About IDAC Theranostics, Inc.
IDAC Theranostics, Inc. was established on April 2, 2012 , by Koji Matsushima, Professor of Graduate School of

Medicine, The University of Tokyo and others, and it has been developing IT1208, which was licensed from Kyowa

Hakko Kirin Co., Ltd. as a drug candidate.

For more information, please visit the companyfs website at

ONO PHAMACEUTICAL CO., LTD, headquartered in Osaka, Japan, is an R&D-oriented pharmaceutical company

committed to creating innovative medicines in specific areas. It focuses especially on the oncology and diabetes areas.

For more information, please visit the companyfs website at

IDAC Theranostics, Inc.
Administrative and Operations